Written by Harry Wolf
Onychomycosis affects around 10 to 20 percent of the global population. It also makes up about 50 percent of all nail disorders, according to a 2025 report published by the International Journal of Advanced Biochemistry Research.
Age-related nail changes, reduced peripheral circulation, cumulative environmental exposure, and comorbid disease… They all contribute to the condition’s prevalence.
Therapeutic decisions are rarely straightforward for clinicians. Efficacy, pathogen identification, comorbidities, drug interaction potential, laboratory monitoring requirements, adherence capacity, and cost… All influence selection between oral and topical antifungal therapies.
A Brief Overview of Onychomycosis
What exactly is onychomycosis? If you are not aware, here is the lowdown: it is a chronic fungal infection involving the nail plate, nail bed, and (in advanced cases) the nail matrix.
Dermatophytes remain the most common etiologic agents, although non-dermatophyte molds and yeasts are increasingly identified in laboratory-confirmed cases, as detailed in an interesting analysis published by Nature’s Scientific Reports.
Accurate organism identification has become increasingly important. Why is that? Quite simply, because therapeutic response varies by species.
Clinically, onychomycosis presents in several morphologic patterns. The following patterns influence both severity assessment and treatment selection:
- Distal lateral subungual disease with progressive onycholysis
- Superficial white onychomycosis affecting the dorsal nail plate
- Proximal subungual disease
- Total dystrophic onychomycosis in advanced and long-standing infections
Chronic fungal colonization can produce subungual hyperkeratosis, nail thickening, discoloration, and friability. Functional consequences include pain, difficulty ambulating, and impaired quality of life.
In patients with diabetes, neuropathy, or peripheral arterial disease, thickened dystrophic nails may contribute to ulceration risk.
Diagnostic confirmation is recommended before initiating systemic therapy.
Antifungal Therapies
Antifungal therapies for onychomycosis are categorized as systemic oral agents or topical transungual therapies. Selection should be determined by:
- Disease severity
- Nail matrix involvement
- Organism type
- Comorbidities
- Patient preference
Systemic agents achieve therapeutic concentrations in the nail bed via bloodstream distribution.
An evidence-based review, published by the National Library of Medicine, confirms that terbinafine, itraconazole, and fluconazole demonstrate clinically meaningful efficacy in treating onychomycosis.
Cure rates? They are generally higher with systemic therapy in moderate-to-severe disease – compared with topical monotherapy.
Topical therapies act directly at the site of infection. A study published by Springer Nature demonstrated superior transungual penetration and antifungal activity of efinaconazole compared with tavaborole, ciclopirox, and several over-the-counter options.
Penetration capacity is clinically relevant. Why? Because the nail plate presents a dense keratin barrier.
Therapeutic strategies? They may include:
- Continuous oral dosing regimens lasting 6 to 12 weeks
- Pulse-dosed oral therapy administered in treatment cycles
- Daily topical application for 48 weeks or longer
- Combination systemic and topical approaches in refractory cases
Mechanistically, allylamines such as terbinafine inhibit squalene epoxidase. They can lead to:
- Ergosterol depletion
- Fungal cell membrane disruption
Azoles such as itraconazole inhibit lanosterol 14-alpha-demethylase, thus impairing ergosterol synthesis. And oxaboroles such as tavaborole inhibit fungal protein synthesis by targeting leucyl-tRNA synthetase.
Understanding pharmacodynamics supports rational therapeutic selection – particularly in complex or recurrent cases, that is.
Selecting Oral Antifungal Therapies
When multiple nails, matrix involvement, or extensive subungual hyperkeratosis are present, systemic therapy remains a first-line approach. Treatment selection needs a high level of attention.
It requires careful evaluation of:
- Efficacy data
- Safety profile
- Comorbid disease
- Drug interaction potential
The Comparative Efficacy of Oral Agents
Multiple comparative trials and meta-analyses demonstrate the following. Continuous oral terbinafine produces higher mycologic and complete cure rates than intermittent itraconazole in dermatophyte toenail onychomycosis.
A double-blind randomized clinical trial, published by the Institute of Tropical Medicine, is worth noting. It compared terbinafine 250 mg daily for 12 weeks with itraconazole 200 mg daily for 12 weeks.
The study reported significantly higher negative mycology rates at 48-week follow-ups in the terbinafine group – 73% versus 46%, in fact. Plus, there were higher rates of near-total clinical cure as well.
These findings support continuous terbinafine as a preferred first-line agent in dermatophyte-predominant disease.
Long-term follow-up data published in JAMA Dermatology further demonstrates that terbinafine can achieve significantly higher sustained mycologic and clinical cure rates, compared with itraconazole, that is. There were lower relapses observed over extended observation periods.
Sustained clearance is clinically meaningful. And that is because? Recurrence contributes to repeated systemic exposure and cumulative cost.
Key comparative considerations? They include:
- Higher sustained mycologic cure rates with continuous terbinafine
- Lower relapse rates in long-term follow-up with terbinafine
- Broader organism coverage with itraconazole
- Dosing flexibility with pulse itraconazole regimens
Yes, itraconazole remains an effective alternative – particularly when non-dermatophyte molds or yeasts are implicated, that is. However… continuous terbinafine therapy continues to demonstrate superior efficacy outcomes in dermatophyte-associated toenail infection.
Safety Profiles and Monitoring
Oral antifungals… They require attention to hepatic safety and drug interaction potential. A safety-focused review published by the National Library of Medicine confirms that terbinafine and itraconazole are generally well tolerated but associated with rare hepatotoxic events.
Hepatic injury is uncommon, yes. But it is clinically significant. So, it warrants appropriate screening.
Baseline liver-function testing is widely recommended before initiating systemic therapy. Monitoring intervals vary depending on the:
- Duration of therapy
- Patient-specific risk factors
Important safety considerations include:
- CYP3A4 inhibition and interaction potential with itraconazole
- Rare hepatotoxicity associated with terbinafine
- Possible negative inotropic effects with itraconazole
- Polypharmacy concerns in older adults
Special Populations and Comorbidities
Patients with diabetes… They represent a clinically significant subgroup. Thickened, dystrophic nails may increase pressure points and contribute to ulcer risk.
Effective fungal eradication may reduce mechanical complications in this population.
Immunocompromised patients may experience atypical or proximal subungual presentations. Broader-spectrum coverage may be considered when non-dermatophyte pathogens are suspected.
Oral therapy may be less suitable in:
- Active or chronic hepatic disease
- History of medication-induced hepatotoxicity
- Inability to adhere to monitoring protocols
- Patient preference for localized therapy
Selecting Topical Antifungal Therapies
Topical therapy… It plays a central role in mild-to-moderate onychomycosis and in patients who cannot tolerate systemic agents. Localized therapy minimizes systemic exposure. However, it requires sustained adherence and realistic counseling regarding duration.
Indications for Topical Monotherapy
Topical monotherapy is typically reserved for limited nail involvement without matrix infection. Treatment duration often approaches 48 weeks because nail growth is slow and drug penetration through keratin is limited.
Appropriate candidates may include:
- Involvement of less than 50 percent of a single nail
- Absence of matrix involvement
- Contraindications to systemic therapy
- Preference to avoid systemic adverse effects
Comparative Effectiveness of Topical Agents
Let’s now reference laboratory evidence published by Springer Nature. It demonstrated significantly greater antifungal activity and transungual penetration for efinaconazole compared with tavaborole, ciclopirox, and evaluated over-the-counter products.
Enhanced penetration may improve mycologic clearance – in carefully selected patients, that is.
Also, the study published by the International Journal of Advanced Biochemistry Research, which we referenced earlier, emphasizes relapse risk and identifies adherence as a primary determinant of success.
Prolonged daily application is required. For what reason? To maintain therapeutic drug levels in the nail plate.
Prescription options include:
- Efinaconazole
- Tavaborole
- Ciclopirox
Clinical selection depends on severity, penetration profile, and tolerability – as well as financial accessibility. So, if you are looking for products containing the active ingredient of efinaconazole, such as Jublia, for example, consider all those elements.
Reviewing the cost of Jublia at PricePro Pharmacy could assist patients in aligning their therapy with affordability.
Combination Therapy and Adjunctive Measures
Combination therapy may be considered in recalcitrant cases. Concomitant topical therapy during or after systemic treatment may reduce recurrence risk – by suppressing residual fungal elements, that is.
Adjunctive strategies? They include:
- Mechanical debridement to reduce nail thickness
- Regular trimming to decrease fungal burden
- Treatment of concomitant tinea pedis
- Environmental hygiene to reduce reinfection
Addressing concomitant skin infection reduces the likelihood of nail reinoculation.
Adherence
Adherence remains a significant barrier in topical therapy. Daily application for extended periods requires sustained patient engagement.
Clinical reviews highlight:
- Nearly year-long treatment timelines
- Gradual cosmetic improvement rather than rapid change
- Higher relapse rates compared with systemic therapy
Clear communication regarding expected time frames and visible milestones is crucial. Because? It improves persistence and therapeutic satisfaction.
Evolving Dermatophyte Resistance Patterns
Emerging antifungal resistance is increasingly influencing clinical decision-making in onychomycosis management. Clinically relevant considerations include:
- Refractory infection despite confirmed adherence
- Recurrence shortly after completing systemic therapy
- History of travel to areas with reported resistant strains
- Prior prolonged or repeated terbinafine exposure
Itraconazole is frequently utilized as an alternative systemic agent when terbinafine resistance is suspected. In documented resistant cases, switching antifungal class has demonstrated clinical improvement.
Molecular diagnostic tools and susceptibility testing may become increasingly relevant in tertiary-care and academic settings.
Also, antifungal resistance reinforces the importance of avoiding empiric systemic therapy without laboratory confirmation. Confirmed diagnosis prior to initiation minimizes unnecessary exposure. And it may reduce selective pressure that contributes to resistance development.
Recurrence Prevention and Long-Term Management
Recurrence remains a persistent challenge in onychomycosis management. Even after an apparent clinical cure.
Data indicates relapse rates of approximately 20 to 25 percent within two years following successful treatment, as summarized in that study published by the International Journal of Advanced Biochemistry Research.
For clinicians, a durable cure requires attention beyond initial fungal eradication.
According to an article by Infection and Drug Resistance, recurrence may be influenced by:
- Biofilm formation
- Untreated concomitant tinea pedis
- Persistent environmental reservoirs
- Host factors such as immunosuppression or diabetes
Addressing those elements can improve long-term outcomes.
Preventive strategies include:
- Treating coexisting tinea pedis concurrently
- Encouraging proper foot hygiene and drying practices
- Disinfecting footwear and nail-care instruments
- Monitoring high-risk patients periodically after cure
Patients with diabetes, peripheral vascular disease, or immunosuppression may require closer follow-ups. Why is that? Quite simply, it is due to elevated complication risk.
Maintenance topical therapy following systemic treatment has been explored as a strategy to reduce recurrence, particularly in individuals with repeated relapse.
Environmental reinoculation also plays a role in recurrence. Shared showers, occlusive footwear, and persistent fungal reservoirs in socks or shoes may facilitate reinfection. Counseling patients about these risks will help to improve long-term therapeutic durability.
Recurrence prevention represents a shift from episodic treatment toward longitudinal management. Integrating preventive counseling into routine care:
- Supports sustained remission
- Reduces cumulative treatment burden
Applying Clinical Judgment in Onychomycosis Management
Let’s recap. Firstly, effective onychomycosis management requires individualized assessment – rather than protocol-driven uniformity, that is.
Oral antifungal therapy generally provides higher complete cure rates in moderate-to-severe disease. Topical antifungal therapy offers a valuable alternative for localized infection or when systemic agents are contraindicated.
Diagnostic confirmation, organism identification, safety monitoring, adherence counseling, and financial accessibility… They all influence therapeutic success.
Hopefully, this article has been helpful. If it has been, take a look at our other relevant content.
Author bio: Harry Wolf is a freelance writer. For almost a decade, he has written on topics ranging from healthcare to business leadership for multiple high-profile websites and online magazines.
References
- Unauthored, 2022, Toenail Fungus, Cleveland Clinic.
https://my.clevelandclinic.org/health/diseases/11303-toenail-fungus
- Unauthored, 2024, Toenail fungus (onychomycosis), Harvard Health Publishing.
https://www.health.harvard.edu/a_to_z/toenail-fungus-onychomycosis-a-to-z
- Bodman, M. A., Syed, H. A., & Krishnamurthy, K., 2025, Onychomycosis, National Library of Medicine.
https://www.ncbi.nlm.nih.gov/books/NBK441853/
- Sinha, R., Rathaur, H., & Mukhopadhyay, S., 2025, Onychomycosis focus in the elderly: Prevalence, diagnosis and treatment strategies, International Journal of Advanced Biochemistry Research.
https://www.biochemjournal.com/archives/2025/vol9issue6/PartB/9-5-104-852.pdf
- Mayengo, R., Petra, N. P., Joseph, O., Ogwang, E., Kitunzi, G. M., Onguti, A. G., & Mirembe, S. K., 2025, Onychomycosis prevalence etiology and associated factors in women using nail cosmetics attending Mbarara regional referral hospital dermatology clinic Uganda, Nature.
https://www.nature.com/articles/s41598-025-30250-8
- De Sa, D. C., Lamas, A. P., & Tosti, A., 2014, Oral therapy for onychomycosis: an evidence-based review, National Library of Medicine.
https://www.ncbi.nlm.nih.gov/books/NBK189719/
- Elabbasi, A., Kadry, A., Joseph, W., Elewski, B., & Ghannoum, M., 2024, Transungual Penetration and Antifungal Activity of Prescription and Over-the-Counter Topical Antifungals: Ex Vivo Comparison, Springer Nature.
https://link.springer.com/article/10.1007/s13555-024-01237-6
- De Backer, M., De Keyser, P., De Vroey, C., & Lesaffre, E., 1996, A 12-week treatment for dermatophyte toe onychomycosis: terbinafine 250 mg/day vs. itraconazole 200 mg/day – a double-blind comparative trial, Institute of Tropical Medicine Antwerp.
- Sigurgeirsson, B., Ólafsson, J. H., Steinsson, J. Þ., Paul, C., Billstein, S., & Evans, E. G. V., 2001, Long-term Effectiveness of Treatment With Terbinafine vs Itraconazole in OnychomycosisA 5-Year Blinded Prospective Follow-up Study, JAMA Network.
https://jamanetwork.com/journals/jamadermatology/fullarticle/478735
- Gupta, A. K., Haas-Neill, S., & Talukder, M., 2023, The safety of oral antifungals for the treatment of onychomycosis, National Library of Medicine.
https://pubmed.ncbi.nlm.nih.gov/37925672/
- Axler, E., & Lipner, S. R., 2024, Antifungal Selection for the Treatment of Onychomycosis: Patient Considerations and Outcomes, Infection and Drug Resistance.
https://www.tandfonline.com/doi/pdf/10.2147/IDR.S431526
Please also review AIHCP’s Managed Health Care Consultant Certification program and CE courses see if it meets your academic and professional goals. These programs are online and independent study and open to qualified professionals seeking a four year certification